Amita Shukla, MBA
Founder & CEO, Vitamita
Ms. Amita Shukla is an innovator and entrepreneur focused on creating, developing, and scaling simple yet powerful ideas for human health, well-being, and potential. She is the founder and CEO of Vitamita and the author of Enduring Edge. Previously, she was a principal at New Enterprise Associates (NEA), one of the world’s largest and most active venture capital firms with close to $17 billion in committed capital, where she spent close to nine years evaluating medical innovations, investing in cutting-edge healthcare start-ups, and working closely with scientists, physicians, and entrepreneurs. Earlier, she was the vice president of AmiKa Corp., a biomedical technology company where she developed and commercialized novel research tools–for which she holds 10 issued patents–until its acquisition by Harvard Bioscience (Nasdaq: HBIO). Previously, she founded two startups and was a healthcare analyst at Merrill Lynch. She has written about innovation for publications such as the MIT Technology Review.
Ms. Shukla regularly mentors startups, advises organizations, and speaks to audiences of innovators, entrepreneurs, and leaders in industry, academia, government, and the military. In 2015, she was appointed as a Mentor in Residence at Johns Hopkins University to help its researchers and physicians realize the potential of their groundbreaking discoveries. She has also served on the Johns Hopkins Medicine Alliance for Science and Technology Development since 2007. In 2010, she was Governor Martin O’Malley’s youngest appointee to the board of Maryland’s Technology Development Corporation (TEDCO), a national leader in seed/early-stage investing. In 2015, she was reappointed by Governor Larry Hogan. Ms. Shukla also serves as a Life Science Council member for Springboard and as a founding board member of the Global Liver Institute, both driven by her passion for mentoring and supporting women entrepreneurs.
Ms. Shukla holds a BA in biochemistry from Harvard, where she was a senior editor at the Harvard Crimson, and an MBA from Stanford, where she led a team that won the university-wide Stanford business plan competition for a novel cardiovascular device.